知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

5 records (took 0.009 seconds)

    Pharmaceutical composition for preventing or treating cardiac arrhythmia
    1.
    发明授权
    Pharmaceutical composition for preventing or treating cardiac arrhythmia 有权

    公开(公告)号：US11761019B2

    公开(公告)日：2023-09-19

    申请号：US16651889

    申请日：2018-09-28

    Applicant: BETHPHAGEN INC.

    Inventor： Min-Ah Lee ,  Tae Hwan Kwak ,  Woo Jin Park

    IPC: A61K38/17 ,  A61P9/06 ,  C12N15/86

    CPC classification number: C12N15/86 ,  A61K38/17

    Abstract: A pharmaceutical composition suitable for preventing or treating cardiac arrhythmia is disclosed. The pharmaceutical composition contains, as an active ingredient, a CCN5 protein or a nucleotide encoding the CCN5 protein. The pharmaceutical composition inhibits the pathological activity of CaMKII, which induces cardiac electrical abnormalities that is the main cause of atrial arrhythmia and ventricular arrhythmia, so as to restore the electrical functions, and inhibits the activity of myofibroblasts causing structural abnormalities. Therefore, the pharmaceutical composition can be effectively used in the prevention or treatment of cardiac arrhythmia.

    Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban
    2.
    再颁专利
    Decoy peptides inhibiting protein phosphatase 1-mediated dephosphorylation of phospholamban 有权

    公开(公告)号：USRE48636E1

    公开(公告)日：2021-07-13

    申请号：US16662518

    申请日：2019-10-24

    Applicant: BethphaGen Inc.

    Inventor： Woo Jin Park ,  Jae Gyun Oh

    IPC: C07K7/06 ,  A61K38/08 ,  A61K38/00 ,  C07K7/00 ,  C07K14/00 ,  C07K14/47

    Abstract: The present invention relates to decoy peptide or polypeptide consisting of a peptide sequence represented by the following Formula I: X1-Ala-X2—X3-Ile-Glu-X4 (I). It is noteworthy that the decoy peptide or polypeptide of the present invention significantly elevates phosphorylation levels of PLB by inhibiting PP1-mediated dephosphorylation. In addition, the decoy peptide or polypeptide provides cardio-protective effects by restoring of SERCA2a activity and inotropic effect of enhancing myocardial contractility. The present invention will contribute greatly to the prevention or treatment of diseases associated with PLB.

    Pharmaceutical composition for prevention or treatment of heart failure
    4.
    发明授权
    Pharmaceutical composition for prevention or treatment of heart failure 有权

    公开(公告)号：US12215362B2

    公开(公告)日：2025-02-04

    申请号：US16651779

    申请日：2018-09-28

    Applicant: BETHPHAGEN INC.

    Inventor： Tae Hwan Kwak ,  Woo Jin Park

    IPC: A61P9/00 ,  A61K35/76 ,  A61K38/17 ,  A61K48/00 ,  C07K14/47 ,  C12N7/00 ,  C12N9/14 ,  C12N15/85 ,  C12N15/86 ,  G01N33/68 ,  A61K38/00

    Abstract: The present invention relates to a pharmaceutical composition for prevention and treatment of heart failure. Specifically, the present invention relates to a gene construct comprising a polynucleotide coding for SERCA2a protein or a fragment thereof and a polynucleotide coding for CCN5 protein or a fragment thereof, and a pharmaceutical composition comprising the same construct as an effective ingredient for preventing or treating heart failure. A pharmaceutical composition for prevention and treatment of heart failure according to the present invention is used in a method for co-expression of SERCA2a protein and CCN5 protein. Designed to exert a synergistic therapeutic effect through SERCA2a protein's function of preventing the loss of cardiomyocytes and increasing the activity of cardiomyocytes and CCN5 protein's function of suppressing the fibrosis of heart cells and tissues, the pharmaceutical composition can be useful for preventing or treating heart failure, which is a complex disorder induced by various etiological factors.

Patent Agency Ranking